DRAFT LETTER

Dr C A Lee MA MD FRCP FRCPath
Director
Haemophilia Centre and Haemostasis Unit
Royal Free Hospital
Pond Street
London
NW3 2QG

[DATE]

Dear Dr Lee

Thank you for your letter of 18 November regarding recombinant Factor VIII.

You will be aware that the Department issued guidance to purchasers to help them in placing contracts for the care of haemophilia patients. Purchasers are guided by expert advice, but must be assured that the money they spend is determined by efficacy of treatment as well as value for money.

I am told by officials that there is no evidence that recombinant Factor VIII is any safer than plasma derived Factor VIII at the present time, and you will also be aware that recombinant Factor VIII contain plasma derived albumin as a carrier. I am also informed that recombinant products themselves are not without side effects.

I understand that Dr Colvin will be meeting with DH officials to discuss concerns about the contracting process in respect of haemophilia care. It may be appropriate to wait for the results of those discussions.

Yours sincerely

CMO